Increased tissue factor pathway inhibitor in patients with acute myocardial infarction

American Journal of Hematology

Volumn 55, Issue 4, 1997, Pages 183-187

  Kamikura, Yuko ^a   Wada, Hideo ^a   Yamada, Atsushi ^a   Shimura, Minori ^a   Hiyoyama, Katsuyo ^a   Shiku, Hiroshi ^a   Tanigawa, Motoaki ^b   Nishikawa, Hideo ^b   Yamada, Norikazu ^a   Isaka, Naoki ^a   Nakano, Takeshi ^a   Kumeda, Kousuke ^c   Kato, Hisao ^d  

^a MIE UNIVERSITY   (Japan)

^b ISE RED CROSS HOSPITAL   (Japan)

^c Chemo Sero Therapeutic Research Institute   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

AMI; Free TFPI; PTCA; TFPI

Indexed keywords

THROMBOPLASTIN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; FEMALE; HEMOSTASIS; HUMAN; LUNG EMBOLISM; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIFIBRINOLYTIC AGENTS; ANTIPLASMIN; ANTITHROMBIN III; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE HYDROLASES; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PULMONARY EMBOLISM; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030805086     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199707)55:4<183::AID-AJH3>3.0.CO;2-O     Document Type: Article

References (19)

1. Davies MJ, Woolf N: Atherosclerosis. What is it and why does it occur? Br Heart J 69(Suppl):S3-S11, 1993.
2. Wilcox JN, Smith KM, Schwartz SM, Gordon D: Localization of tissue factor in the normal vessel wall and in the atherosclerotic olaque. Proc Natl Acad Sci USA 86:2639-2643, 1989.
3. Sandest PM, Sirnes PA, Abildgaard U: Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br J Haematol 72:391-396, 1989.
4. Moor E, Hamsten A, Karpe F, Bavenholm P, Blomback M, Silveria A: Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemost 71:707-712, 1994.
5. Wun T-C, Kretzmer KK, Girard TJ, Miletich JP, Broze G Jr: Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor show that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 263:6001-6004, 1988.
6. Broze G, Girard TJ, Novotny WF: The lipoprotein-associated coagulation inhibitor. In Colter BS (ed): "Progress in Haemostasis and Thrombosis." vol. 10. Philadelphia: WB Saunders, 1990, pp 243-268.
7. Rapaport SI: The extrinsic pathway inhibitor, a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 66:6-15, 1991.
8. Novotny WF, Brown SG, Mieltich JP, Rader DJ, Broze GJ: Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 78:387-393, 1991.
9. Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U: Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coag Fibr 2:713-721, 1991.
10. Brandzaeg P, Sandset PM, Joo GB, Obstebo R, Abildgaard U, Kierulf P: The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 55:459-470, 1989.
11. Kobayashi M, Wada H, Wakita Y, Shimura M, Nakase T, Hiyoyama K, Nagaya S, Minami N, Nakano T, Shiku H: Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 73:10-14, 1995.
12. Valentin S, Nordfang C, Bregengard C, Wildgoose P: Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins. Blood Coag Fibr 4:713-720, 1993.
13. Abumiya T, Enjyoji K, Kokawa T, Kamikubo Y, Kato H: An antitissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. J Biochem 118:178-182, 1995.
14. Kokawa T, Enjyoji K, Kumeda K, Kamikubo Y, Harada-shiba M, Koh H, Tsushima M, Yamamoto A, Kato H: Measurement of free form of tissue factor pathway inhibitor (TFPI) antigen in hyperlipidemia: Relationship between free form and endothelial cell-associated forms of TFPI. Arterioscl Thromb Vasc Biol 16:802-808, 1996.
15. Kamei S, Kamikubo Y, Hamuro T, Fujimoto H, Ishihara M, Yonemura H, Miyamoto S, Funatsu A, Enjyoji K, Abumiya T, Miyata T, Kato H: Amino acid sequence and inhibitory activity of rhesus monkey tissue factor pathway inhibitor (TFPI): Comparison with human TFPI. J Biochem 115:708-714, 1994.
16. Kokawa T, Abumiya T, Kimura T, Harada-Siba M, Koh H, Ysushima M, Yamamoto A, Kato H: Tissue factor pathway inhibitor (TFPI) activity in human plasma: Measurement of lipoprotein-associated and free forms in hyperlipidemia. Arterioscl Thromb Vasc Biol 15:504-510, 1995.
17. Wada H, Minamikawa K, Wakita Y, Nakase T, Kaneko T, Ohiwa M, Tamaki S, Deguchi K, Shirakawa S, Hayashi T, Suzuki K: Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation. Am J Hematol 44:85-88, 1993.
18. Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, Mori Y, Shiku H: Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 52:165-170, 1996.
19. Hoppensteadt DA, Walenga JM, Fasanella, A, Jeske W, Fareed J: TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 77:175-185, 1995.